
Targeted Oncology
Advertisement
Articles by Targeted Oncology


Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.




A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.




















Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.




Advertisement
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
3
FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer
4
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
5
